CGT Catapult appoints Jeanette Evans as chief business officer
UK-based industry accelerator the Cell and Gene Therapy Catapult (CGT Catapult) today announces that Jeanette Evans has been appointed chief business officer (CBO), taking over from Sharon Brownlow, with effect in August 2023.
Ms Evans is a senior business development executive with over 25 years' experience in the pharmaceutical industry including working for leading companies such as AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK).
She joins the CGT Catapult from U cell therapy specialist Adaptimmune (Nasdaq: ADAP), where she most recently served as vice president business development, leading the business development team. Through collaborations and partnerships with industry and academia, her team supported the advancement of Adaptimmune’s cell therapies for the treatment of patients with solid tumours. During her extensive career to date, Jeanette has had the opportunity to lead business development projects and transactions globally, across many therapeutic areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze